Systemic lupus erythematosus (SLE) is a devastating disease that a ects mostly women in their childbearing years. Shortand medium-term survival of patients with SLE has greatly improved recently, but long-term prognosis remains poor.
is stresses the need to identify markers of SLE progression to nephritis, such as vascular endothelial growth factor (VEGF). Understanding the complex regulation of VEGF metabolism in patients with SLE could provide physicians with invaluable information for the treatment or prevention of lupus nephritis.
SLE is an autoimmune disease characterized by antibodies directed against various nuclear autoantigens, particularly components of chromatin, such as double-stranded DNA, histones, nucleosomes, and ribonucleoproteins. 1 Nephritis is one of the main causes of morbidity and mortality in SLE. Important features of lupus nephritis include the deposition of auto antibodies within the glomerular and tubular basement membranes, and a local inflammatory reaction that includes immune complex vasculitis with endothelial cell damage. 2 Ultimately, this leads to proteinuria and a decline in renal function in association with glomerular sclerosis and tubulointerstitial brosis. Elution of anti-DNA antibodies from lupus kidneys and the correlation between increased antibody levels and renal ares, as well as the pathogenic role of these antibodies in experimental murine models, show that autoimmune anti-DNA antibodies play a crucial role in injury to both the glomerular and the tubular compartments. 3 Glomerular damage has been linked to proteinuria, indicating its importance in the pathogenesis of lupus nephritis. e tubular compartment also plays an important role, as tubular atrophy and interstitial brosis are predictors of poor renal outcome in lupus patients. 4 Events subsequent to deposition of injurious immune complexes leading to renal injury have not been well understood but could involve locally produced mediators such as VEGF.
The role of VEGF in the patho genesis of lupus nephritis has not been elucidated. Although both the serum level
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In kidneys from patients with lupus nephritis, Avihingsanon et al. report that decreased renal expression of vascular endothelial growth factor (VEGF) may be a protective mechanism against renal damage and a predictive factor for loss of kidney function. This finding could be an important tool for understanding the role of VEGF in renal disease and for the early detection of lupus nephritis, as the long-term prognosis still remains poor despite improvement in medium-term survival of patients.
Kidney International (2009) 75, 1251 -1253. doi: 10.1038/ki.2009.101 of VEGF and the titer of anti-DNA antibodies are elevated in patients with lupus, they do not correlate. VEGF could play a protective role in the preservation of organ function, probably through maintenance of endothelialcell function and integrity of vasculature.
Avihingsanon et al. 5 (this issue) show that VEGF expression is lower in lupus kidneys and that renal VEGF content is negatively correlated with glomerular endocapillary proliferation, crescent formation, and high histological activity index. is nding is of particular interest because both serum and urine levels of VEGF are signi cantly increased in patients with lupus nephritis. Lower synthesis of VEGF in lupus kidneys is likely a consequence of the initial kidney injury, due to circulating autoantibodies. As the serum level of VEGF is increased in lupus patients, and VEGF is considered a protective factor, this raises an important question.
Why isn ' t VEGF protecting the kidney in patients with lupus?
An increased serum level of VEGF implies that glomerular endothelial cells are presented with amounts of VEGF that should be su cient to ensure their integrity. However, lupus nephritis is associated with signi cant endothelial cell injury. 2 A possible explanation is that, in addition to VEGF, the serum level of the soluble form of VEGF receptor-1 (sFlt1) is also signi cantly increased in patients with lupus nephritis. 6 Because this receptor, in both its membrane form (Flt1) and its soluble form (sFlt1), has a tenfold higher afnity for VEGF than VEGF receptor-2 / Flk1, 6 such an increase in serum sFlt1 could e ectively bind circulating VEGF. As a consequence, less VEGF would be available to the glomerular endothelial cells, and this could explain endothelial cell injury and apoptosis observed in patients with lupus nephritis. Alteration of VEGF signaling in glomerular endothelial cells could also favor the expression of adhesion molecules, such as E-selectin, vascular cell adhesion see original article on page 1340 tubule epithelial cells through two cellsurface molecules, one with a molecular weight of 100 -120 kDa, and the other of 36 kDa. 1 Although these molecules have not been identi ed in these studies, one possible candidate is hevin, a protein of 664 amino acids that has a molecular weight of about 120 kDa. Binding of anti-DNA antibodies to hevin on the surface of lymphocytes triggers the internalization and nuclear localization of the antibodies. Binding of anti-DNA antibodies from lupus patients to proximal tubule epithelial cells leads to rapid internalization and triggers an in ammatory response characterized by increased synthesis of interleukin-6 and tumor necrosis factor-. 10 It is tempting to speculate that this in ammatory response in proximal tubule epithelial cells is accompanied by decreased VEGF synthesis. -Actinin is another membrane protein that is bound by anti-DNA antibodies. Within the kidney, -actinin is predominantly localized in the podocyte foot processes and mesangial cells, and anti-DNA antibodies puri ed from patients with lupus nephritis bind strongly to -actinin. Whether this leads to internalization of antibodies and in ammatory response, and therefore to decreased synthesis of VEGF, remains to be determined.
Decreased renal VEGF as a progression factor of kidney injury?
Decreased expression of VEGF in kidneys from patients with established diabetic nephropathy has recently been reported. 11 Low renal VEGF was correlated with peritubular capillary rarefaction, brosis, and proteinuria. is suggests that reduction in renal VEGF could contribute to endothelial cell injury, causing capillary rarefaction, and leading to tubular atrophy, interstitial brosis, and ultimately proteinuria. A similar mechanism could play a role in the development of lupus nephritis.
The discovery that decreased renal VEGF may be a predictive factor for short-term loss of kidney function in lupus patients could be an important tool to allow treatment of renal are before kidney damage is too severe; however, since renal biopsy is usually done a er molecule-1, and intercellular adhesion molecule-1, observed in lupus patients. Because damage to glomerular endothelial cells causes increased exposure of the glomerular basement membrane to the circulation, and circulating DNA can bind directly to it, 7 this could permit circulating autoantibodies to bind glomerular basement membrane-bound DNA.
is deposition of immune complexes on the glomerular basement membrane could in turn attract monocytes, which would bind the endothelial cells expressing these adhesion molecules.
is could explain the development of vasculitis in spite of a high level of circulating VEGF. Activated macrophages in the kidney produce proin ammatory cytokines, which induce a chronic inammatory response that would culminate in extracellular matrix expansion in the glomeruli and the tubulointerstitial space, and proteinuria ( Figure 1 ) .
What is the mechanism of decreased VEGF synthesis in lupus kidneys?
e main site of VEGF production in the kidney has long been thought to be the podocytes; 8 however, recent studies 5,9 have shown substantial production of VEGF in the proximal tubule epithelial cells. Avihingsanon et al. 5 show that expression of renal VEGF decreases in both podocytes and proximal tubule epithelial cells. One possible explanation could be the passage of autoimmune antibodies through the leaky glomerular basement membrane into the urine.
is allows immune complexes to be in direct contact with both podocytes and proximal tubule epithelial cells. Anti-DNA antibodies can directly interact with non-DNA antigens present on the surface of several cell types, such as laminin, heparan sulfate, and collagen type IV. 1 In addition, these antibodies can bind proximal clinical indices of renal injury are manifest, one has to look for other VEGF parameters. As it is possible that the serum level of VEGF increases before the renal content of VEGF decreases, this could allow precise timing of intervention. It is important to test this hypothesis in the clinical setting. Understanding the complex regulation of VEGF metabolism in lupus patients could provide physicians with invaluable information for the treatment or prevention of lupus nephritis.
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Arachidonic acid (AA) has long been found to be metabolized by cyclooxygenase and lipoxygenase enzymes to prostaglandins, prostacyclin, thromboxane, leukotrienes, and 5-, 12-, and 15-hydroxyeicosatetraenoic acid (HETE). Recently, it was found that AA is also metabolized by the -hydroxylase cytochrome P450 (CYP) enzymes to form epoxyeicosatrienoic acids, dihydroxyeicosatetraenoic acids, 19-HETE, 20-HETE, and other forms of HETE. The metabolites of AA generated by the P450 enzymes have been found to play important roles in the regulation of vascular tone in renal, cerebral, coronary, and skeletal muscle arterioles and in pulmonary circulation. 1,2 More than 500 CYP genes have been identified; among them, CYP4F2 , CYP4A11 , and CYP4F3B are thought to be the major genes involved in metabolizing AA to form 20-HETE. 1,2 20-HETE is a potent constrictor of small arteries and arterioles; however, in the kidney, 20-HETE also regulates tubular sodium reabsorption in the proximal tubule, as well as in the thick ascending limb of Henle ' s loop via inhibition of Na + -K + -ATPase activities or Na + -K + -2Clcotransport. Therefore, the influence of 20-HETE on blood pressure remains difficult to predict: it could play either a prohypertensive or an antihypertensive role, depending on its action as a vasoconstrictor or a sodium reabsorption inhibitor in renal tubules. 1,3 In addition, studies in human and animal models also suggest diverse effects of CYP gene function on blood pressure. In humans, functional polymorphism analysis demonstrated that diverse consequences resulted from genetic polymorphism: the CYP4F2 GA / AA genotype was significantly associated with an increase in both 20-HETE excretion and systolic blood pressure, whereas the CYP4A11 CC / TC genotype was significantly associated with a reduction in 20-HETE excretion but
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The cytochrome P450-derived 20-hydroxyeicosatetraenoic acid (20-HETE) has known function that plays opposite roles in blood pressure: prohypertensive and antihypertensive. Liu et al. report that the CYP4F2 transgene, driven under an exogenous promoter, increases 20-HETE production and is associated with increased blood pressure in vivo . This study provides evidence for the first time that overexpression of P450 4F2 enzyme results in higher production of 20-HETE, which promotes hypertension. The significance of this transgenic mouse model is further discussed.
